Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.

Journal article

We have analyzed the factors associated with engraftment in 216 recipients of T-cell depleted allogeneic HLA identical sibling marrow transplants using Campath 1 monoclonal antihuman lymphocyte (CD52) antibodies. The patient population consisted of 168 patients with hematologic malignancies, 26 with severe aplastic anemia (SAA), and 22 with hemoglobinopathies, half of whom received marrow treated in vitro with Campath-1M (IgM) and half received marrow with Campath-1G (IgG2b isotype). Patients...

Expand abstract

Authors: Naparstek, E; Delukina, M; Or, R; Nagler, A; Kapelushnik, J

• Publication status: Published
• Journal: Experimental hematology
• Volume: 27
• Issue: 7
• Pages: 1210-1218
• Publication date: 1999-07-01
• DOI: 10.1016/s0301-472x(99)00052-1
• EISSN: 1873-2399
• ISSN: 0301-472X
• Language: English
• Keywords: Antibodies, Neoplasm; Transplantation Conditioning; Treatment Outcome; Age Factors; Sex Factors; Nuclear Family; Antibodies, Monoclonal, Humanized; Bone Marrow Purging; Male; Leukemia; ABO Blood-Group System; Rats; Female; beta-Thalassemia; Transplantation, Homologous; Anemia, Aplastic; Immunosuppression; Animals; Antibodies, Monoclonal; Graft vs Host Disease; Multivariate Analysis; Lymphocyte Depletion; Graft Rejection; Graft Survival; Bone Marrow Transplantation; Humans; Leukemia, Myeloid, Acute